The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for PD


(May 16, 2016) - NeuroDerm announced the start of patient enrollment in a long-term safety study (trial 012) of the company’s continuously administered subcutaneous levodopa/carbidopa (LD/CD) formulation used in both ND0612H and ND0612L. The one-year international, open label study will investigate the long-term safety of low and high dose regimens of ND0612.  Read more…



Article Archive

back